Positron emission tomography imaging of tumor angiogenesis and monitoring of antiangiogenic efficacy using the novel tetrameric peptide probe 64Cu-cyclam-RAFT-c(-RGDfK-)4

Angiogenesis

Volumn 15, Issue 4, 2012, Pages 569-580

  Jin, Zhao Hui ^a   Furukawa, Takako ^a   Claron, Michael ^b   Boturyn, Didier ^b   Coll, Jean Luc ^c   Fukumura, Toshimitsu ^a   Fujibayashi, Yasuhisa ^a   Dumy, Pascal ^b   Saga, Tsuneo ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b UNIVERSITÉ JOSEPH FOURIER   (France)

^c INSERM   (France)

Author keywords

Angiogenesis; Multimeric RGD peptide; Positron emission tomography; TSU 68

Indexed keywords

CD31 ANTIGEN; CYCLAM REGIOSELECTIVELY ADDRESSABLE FUNCTIONALIZED TEMPLATE 4 CYCLO(ARGINYLGLYCYLASPARTYLPHENYLALANYLLYSINE) CU 64; ORANTINIB; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RESPONSE; DRUG UPTAKE; EMBRYO; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MICROVASCULATURE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

MUS MUSCULUS;

EID: 84874769552     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-012-9281-1     Document Type: Article

References (40)

1. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(Suppl 16):15-18.
2. Prager GW, Poettler M (2011) Angiogenesis in cancer. Basic mechanisms and therapeutic advances. Hamostaseologie 32: 105-114.
3. Augustin HG (2003) Translating angiogenesis research into the clinic: the challenges ahead. Br J Radiol 76:S3-10. (Pubitemid 39530311)
4. Rosen L (2000) Antiangiogenic strategies and agents in clinical trials. Oncologist 5(Suppl 1):20-27. (Pubitemid 30225453)
5. Wu HC, Huang CT, Chang DK (2008) Anti-angiogenic therapeutic drugs for treatment of human cancer. J Cancer Mol 4:37-45.
6. Wahl O, Oswald M, Tretzel L, Herres E, Arend J, Efferth T (2011) Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Curr Med Chem 18: 3136-3155.
7. Bowden DJ, Barrett T (2011) Angiogenesis imaging in neoplasia. J Clin Imaging Sci 1:38.
8. Rudin M, Weissleder R (2003) Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2:123-131. (Pubitemid 37361644)
9. Almuhaideb A, Papathanasiou N, Bomanji J (2011) 18F-FDG PET/CT imaging in oncology. Ann Saudi Med 31:3-13.
10. Sun X, Yan Y, Liu S, Cao Q, Yang M, Neamati N, Shen B, Niu G, Chen X (2011) 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med 52:140-146.
11. Yang M, Gao H, Yan Y, Sun X, Chen K, Quan Q, Lang L, Kiesewetter D, Niu G, Chen X (2011) PET imaging of early response to the tyrosine kinase inhibitor ZD4190. Eur J Nucl Med Mol Imaging 38:1237-1247.
12. Stromblad S, Cheresh DA (1996) Integrins, angiogenesis and vascular cell survival. Chem Biol 3:881-885. (Pubitemid 27017086)
13. Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H (1996) Structural and functional aspects of RGDcontaining cyclic pentapeptides as highly potent and selective integrin aVb3 antagonists. J Am Chem Soc 118:7461-7472. (Pubitemid 26279800)
14. Haubner R (2006) aVb3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 33(Suppl 1):54-63.
15. Dijkgraaf I, Beer AJ, Wester HJ (2009) Application of RGDcontaining peptides as imaging probes for aVb3 expression. Front Biosci 14:887-899.
16. Choyke PL (2011) Pilot study of FPPRGD2 for imaging aVb3 integrin-how integral are integrins? Radiology 260:1-2.
17. Beer AJ, Kessler H, Wester HJ, Schwaiger M (2011) PET imaging of integrin aVb3 expression. Theranostics 1:48-57.
18. Jung KH, Lee KH, Paik JY, Ko BH, Bae JS, Lee BC, Sung HJ, Kim DH, Choe YS, Chi DY (2006) Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J Nucl Med 47:2000-2007.
19. Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel PS, Weber WA (2009) Noninvasive imaging of aVb3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res 69:3173-3179.
20. Morrison MS, Ricketts SA, Barnett J, Cuthbertson A, Tessier J, Wedge SR (2009) Use of a novel Arg-Gly-Asp radioligand, 18FAH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med 50:116-122.
21. Battle MR, Goggi JL, Allen L, Barnett J, Morrison MS (2011) Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled aVb3-integrin and aVb5- integrin imaging agent. J Nucl Med 52:424-430.
22. Boturyn D, Coll JL, Garanger E, Favrot MC, Dumy P (2004) Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J Am Chem Soc 126: 5730-5739. (Pubitemid 38621412)
23. Galibert M, Jin ZH, Furukawa T, Fukumura T, Saga T, Fujibayashi Y, Dumy P, Boturyn D (2010) RGD-cyclam conjugate: synthesis and potential application for positron emission tomography. Bioorg Med Chem Lett 20:5422-5425.
24. Jin ZH, Furukawa T, Galibert M, Boturyn D, Coll JL, Fukumura T, Saga T, Dumy P, Fujibayashi Y (2011) Noninvasive visualization and quantification of tumor aVb3 integrin expression using a novel positron emission tomography probe, 64Cu-cyclam- RAFT-c(-RGDfK-)4. Nucl Med Biol 38:529-540.
25. Jin ZH, Josserand V, Foillard S, Boturyn D, Dumy P, Favrot MC, Coll JL (2007) In vivo optical imaging of integrin aVb3 in mice using multivalent or monovalent cRGD targeting vectors. Mol Cancer 6:41-50.
26. Yoshitomi H, Kobayashi S, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Miyazaki M (2008) Specific expression of endoglin (CD105) in endothelial cells of intratumoral blood and lymphatic vessels in pancreatic cancer. Pancreas 37:275-281.
27. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9-22.
28. Sancey L, Ardisson V, Riou LM, Ahmadi M, Marti-Batlle D, Boturyn D, Dumy P, Fagret D, Ghezzi C, Vuillez JP (2007) In vivo imaging of tumour angiogenesis in mice with the aVb3 integrin-targeted tracer 99mTc-RAFT-RGD. Eur J Nucl Med Mol Imaging 34:2037-2047. (Pubitemid 350212119)
29. Ahmadi M, Sancey L, Briat A, Riou L, Boturyn D, Dumy P, Fagret D, Ghezzi C, Vuillez JP (2008) Chemical and biological evaluations of an 111In-labeled RGD-peptide targeting integrin Alpha(V) Beta(3) in a preclinical tumor model. Cancer Biother Radiopharm 23:691-700.
30. Sancey L, Garanger E, Foillard S, Schoehn G, Hurbin A, Albiges- Rizo C, Boturyn D, Souchier C, Grichine A, Dumy P, Coll JL (2009) Clustering and internalization of integrin aVb3 with a tetrameric RGD-synthetic peptide. Mol Ther 17:837-843.
31. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M (2005) Noninvasive visualization of the activated aVb3 integrin in cancer patients by positron emission tomography and p18F]galacto-RGD. PLoS Med 2:e70.
32. Liu S, Liu Z, Chen K, Yan Y, Watzlowik P, Wester HJ, Chin FT, Chen X (2010) 18F-labeled galacto and PEGylated RGD dimers for PET imaging of aVb3 integrin expression. Mol Imaging Biol 12:530-538.
33. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington JM (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152-4160. (Pubitemid 30636598)
34. Ueda Y, Shimoyama T, Murakami H, Yamamoto N, Yamada Y, Arioka H, Tamura T (2011) Phase I and pharmacokinetic study of TSU-68, a novelmultiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. Cancer Chemother Pharmacol 67:1101-1109.
35. Murakami H, Ueda Y, Shimoyama T, Yamamoto N, Yamada Y, Arioka H, Tamura T (2011) Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors. Cancer Chemother Pharmacol 67:1119-1128.
36. Melis M, Bijster M, de Visser M, Konijnenberg MW, de Swart J, Rolleman EJ, Boerman OC, Krenning EP, de Jong M (2009) Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours. Eur J Nucl Med Mol Imaging 36:1968-1976.
37. Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, Gotthardt M, Boerman OC (2010) Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 51:1049-1058.
38. Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, McParland B, Cohen PS, Hui AM, Palmieri C, Osman S, Glaser M, Turton D, Al-Nahhas A, Aboagye EO (2008) Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 49:879-886. (Pubitemid 351793427)
39. Mittra ES, Goris ML, Iagaru AH, Kardan A, Burton L, Berganos R, Chang E, Liu S, Shen B, Chin FT, Chen X, Gambhir SS (2011) Pilot pharmacokinetic and dosimetric studies of 18F-FPPRGD2: a PET radiopharmaceutical agent for imaging aVb3 integrin levels. Radiology 260:182-191.
40. Lang L, Li W, Guo N, Ma Y, Zhu L, Kiesewetter DO, Shen B, Niu G, Chen X (2011) Comparison study of [18F]FAl-NOTAPRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem 22: 2415-2422.